血清白细胞介素-35水平对索拉菲尼联合非规则性肝切除术治疗的原发性肝癌患者临床疗效及预后的影响

目的 探讨血清白细胞介素-35(IL-35)水平对索拉菲尼联合非规则性肝切除术治疗的原发性肝癌(PLC)患者临床疗效及预后的影响.方法 选取66例PLC患者,所有患者均接受非规则性肝切除术,术后1周口服索拉菲尼;采用酶联免疫吸附试验测定患者术前IL-35水平,将患者分为高IL-35组33例和低IL-35组33例;比较两组患者的临床疗效、不良反应发生情况,以及不同生存时间患者的IL-35水平.结果 高IL-35组目标病灶、非目标病灶治疗总体有效率均高于低IL-35组(P<0.05);高IL-35组和低IL-35组的不良反应发生率分别为18.18%(6/33)和12.12%(4/33),两组间比较差异无统计学意义(P>0.05);短期生存组(生存时间≤2年)血清IL-35含量为(64.17±19.21)pg/ml,低于长期生存组(生存时间>2年)的(106.19±21.56)pg/ml(P<0.05).结论 IL-35可能是影响索拉菲尼联合非规则性肝切除术治疗PLC患者临床效果及预后的重要因素.

Effect of serum interleukin-35 level on clinical efficacy and prognosis of primary liver cancer patients receiving sorafenib combined with irregular hepatectomy

Objective To investigate the effect of serum interleukin-35(IL-35) level on the clinical efficacy and prognosis of primary liver cancer(PLC) patients receiving sorafenib combined with irregular hepatectomy.Methods Sixty-six patients with PLC were enrolled.All patients underwent irregular liver hepatectomy and were orally treated with sorafenib after one week of surgery.The IL-35 level before surgery was measured by enzyme-linked immunosorbent assay,then the patients were divided into high IL-35 group(n=33) and low IL-35 group(n=33).The clinical efficacy and the incidence of adverse reactions were compared between the two groups.The IL-35 levels were compared between the patients with different survival times.Results The overall therapeutic effective rates of target lesion and non-target lesion in the high IL-35 group were significantly higher than those in the low IL-35 group(P<0.05).The incidence rates of adverse reactions in the high IL-35 group and low IL-35 group were 18.18%(6/33) and 12.12%(4/33) respectively,but there was no significant difference between the two groups(P>0.05).The serum IL-35 level in the short-term survival time(equal to or less than 2 years)group was significantly lower than that in the long-term survival time(more than 2 years) group(64.17±19.21 pg/ml vs.106.19±21.56 pg/ml;P<0.05).Conclusion IL-35 may be an important factor influencing the clinical efficacy and prognosis of PLC patients receiving sorafenib combined with irregular hepatectomy.